Sign up United Kingdom
ImmuPharma PLC (LON:IMM)

ImmuPharma PLC (LON:IMM)


Share Price
14.55 p
Change
1.725 (13.45 %)
Market Cap
£20.29 m
Proactive Investors - Run By Investors For Investors

ImmuPharma PLC RNS Release

Interim Results


RNS Number : 9046B
Immupharma PLC
26 September 2018
 

 

26 SEPTEMBER 2018

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

INTERIM RESULTS ANNOUNCEMENT
for the six months ended 30 June 2018

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2018 (the "Period").

 

Key Highlights

 

LupuzorTM

 

·     Lupuzor™ demonstrated a superior response rate over placebo (52.5% vs 44.6% "responders") in the primary analysis on the Full Analysis Set of all 202 patients. However, due to the high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.
 

·     Across the whole study population, in those patients who had anti-dsDNA autoantibodies, LupuzorTM demonstrated a superior response rate over placebo (61.5% vs 47.3%, p = 0.0967).  Although these results were not statistically significant, further data analysis demonstrated that in the Europe cohort (130 patients) LupuzorTM plus standard of care showed statistically significant reductions  in disease activity compared to placebo plus standard of care in 79 patients who were anti-dsDNA autoantibody positive (71.1% vs 48.8%, p = 0.0218).
 

·     The study confirmed the outstanding safety profile of LupuzorTM, with no serious adverse events reported. 

 

·      As announced on 7 September 2018, agreement signed with a specialist provider to enter LupuzorTM into a 'Managed Access Programme'.
 

·      Open label extension study completes recruitment.
 

 

Other programs

 

·     Nucant (cancer) program - Clinical Development Collaboration with Incanthera Limited.
 

·     Peptide platform program / Ureka subsidiary - ImmuPharma to begin divestment process.

 

Financial Position

 

·     £10 million fundraising (before expenses) successfully completed in January 2018.

 

·     Stable financial performance over the Period, in line with market expectations

Net assets of £9.9 million (31 December 2017: £3.6 million)

Loss for the period of £4.1 million (H1 2017:  £3.0 million)

§ Research and Development expenses of £2.5 million (H1 2017: £2.3 million)

Basic and diluted loss per share of 2.94p (H1 2017: 2.34p)

 

Appointment of new joint brokers

 

·     Stanford Capital Partners and SI Capital appointed as joint brokers, working in conjunction with current NOMAD and broker, Northland Capital Partners.

 

Commenting on the Interims and outlook Tim McCarthy, Chairman, said:

 

"The Board is pleased to announce the interim results for the six months ended 30 June 2018.  It has been a busy period for the Board following the announcement of the Phase III trial results for Lupuzor in April 2018. We remain focused on delivering a business strategy which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, resources and knowhow.  We were obviously disappointed with the outcome of the Phase III trial results but are excited to be progressing the Managed Access Programme with a new strategic partner, which allows lupus patients early access to LupuzorTM. In the medium term, we remain focussed on achieving the full regulatory approval of LupuzorTM which we believe has the potential to be a ground breaking drug for lupus patients with blockbuster potential in commercial terms. 

 

Our Nucant programme and Ureka subsidiary have been part of our portfolio for a number of years.  We are equally excited by the potential of both.  We believe the strategy we announced earlier this month, together with a robust financial position, will create enhanced value for shareholders going forward."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

 

For further information please contact:

ImmuPharma PLC

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

 

Dimitri Dimitriou, Chief Executive Officer

 

Tracy Weimar, Vice President, Operations and Finance

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited, Nomad & Joint Broker

+44 (0) 20 3861 6625

David Hignell, Jamie Spotswood, Dugald Carlean, Corporate Finance

Rob Rees, Corporate Broking

 

 

Stanford Capital Partners, Joint Broker                     

Patrick Claridge

Chris Coleman

 

+44 (0) 20 3815 8880

SI Capital, Joint Broker

Nick Emerson

+44 (0) 1483 413500

 

 

CHAIRMAN'S STATEMENT

 

INTERIM HIGHLIGHTS

 

The first half of 2018 saw the completion of our pivotal Phase III trial for LupuzorTM, our candidate for the treatment of lupus.  Top-line results were announced on 17 April 2018 with further analysis provided on 29 May 2018.  Following these results, ImmuPharma has recently signed an agreement with a specialist provider to distribute LupuzorTM via a Managed Access Programme.  This will allow lupus patients early access to LupuzorTM prior to any regulatory filing. 

 

ImmuPharma has, on 6 September 2018, signed a Heads of Terms on a clinical development collaboration for the Nucant cancer programme with Incanthera Limited, a specialist oncology development company.  Further, following an extensive review, it has been decided that the Company's Ureka subsidiary which focuses on peptide treatments for metabolic disorders is not part of the ongoing strategy of ImmuPharma which is now fully focused on utilising its resources to develop late stage assets.  Consequently, we are beginning the process of divesting Ureka.

 

In other developments, we were pleased to have completed a successful fund raising of £10 million (before expenses) in January 2018.  The fund raising was supported by long term shareholders and the addition of new institutional and private investors.

 

LupuzorTM Phase III results and next steps

 

The Phase III trial was a double-blind, randomised, placebo-controlled trial. The study involved patients being dosed for one year, receiving 0.2mg once per month subcutaneously. 293 patients were screened illustrating the demand from physicians for a new, safe and effective treatment for lupus.  Of these, the required 202 patients were successfully recruited and randomised (dosed).  Patients participated in the trial in 7 countries across 28 sites. 

 

The clinical trial was undertaken primarily by Simbec-Orion, an international clinical research organisation, who specialises in rare and orphan conditions and has previous direct experience in lupus trials. This was a pivotal study designed to demonstrate the safety and efficacy of Lupuzor.

 

Lupuzor™ demonstrated a superior response rate over placebo (52.5% vs 44.6% "responders") in the primary analysis on the Full Analysis Set of all 202 patients. However, due to the high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.

 

Across the whole study population, in those patients who had anti-dsDNA autoantibodies, LupuzorTM demonstrated a superior response rate over placebo (61.5% vs 47.3%, p = 0.0967).  Although these results were not statistically significant, further data analysis demonstrated that in the Europe cohort (130 patients) LupuzorTM plus standard of care showed statistically significant reductions  in disease activity compared to placebo plus standard of care in 79 patients who were anti-dsDNA autoantibody positive (71.1% vs 48.8%, p = 0.0218). 

 

The study confirmed the outstanding safety profile of LupuzorTM, with no serious adverse events reported. 

 

Scientific literature indicates that approximately 60% - 70% of patients diagnosed for lupus are anti-dsDNA autoantibody positive.  These proportions were seen in the Europe cohort (60.8% of patients) and could therefore be considered as representative of the overall lupus population.

 

In those patients who were anti-dsDNA autoantibody negative, there was almost no difference in disease activity reduction between the active group and the comparator group.  Anti-dsDNA autoantibodies are a recognised biomarker for Systemic Lupus Erythematosus. 

 

This finding indicates that the activity of LupuzorTM could be correlated with the presence of anti-dsDNA autoantibodies in lupus patients.  ImmuPharma believes that predictive biomarkers, such as anti-dsDNA autoantibodies, could allow identification of patients that are more likely to respond positively to treatment with LupuzorTM

 

LupuzorTM next steps - Managed Access Program

 

ImmuPharma is planning to move forward with a Managed Access Program for LupuzorTM.  Recognising that lupus is a disease with significant unmet medical need and given the advanced level of clinical trial investigation completed, ImmuPharma would like to meet demand for access to LupuzorTM by lupus patients who, together with their physicians, request it. 

 

Extension study

 

The LupuzorTM extension study, which was announced on 18 January 2018, is continuing and recruitment is now complete with a total of 62 patients eligible from the original Phase III trial.  We believe that this will provide more valuable information on the potential efficacy and safety of LupuzorTM.  The study is anticipated to report results in Q2 2019.

 

Nucant Platform

 

A number of options have been under review to develop the Company's Nucant cancer programme, which has demonstrated promising results in two Phase I trials (safety and dose-finding studies).

 

In order to progress the programme, on 6 September 2018 ImmuPharma signed Heads of Terms on a clinical development collaboration for the Nucant cancer programme, with Incanthera Limited ("Incanthera"), a specialist oncology development company.

 

Key highlights of the Heads of Terms are summarised below:

 

·     Incanthera, based on its positive due-diligence on the Company's Nucant technology, will license in and take up the continued clinical development of the Nucant cancer programme as an integral part of its own cancer development portfolio.

·     As an integral part of the collaboration, upon signing the Heads of Terms, ImmuPharma has invested £2m into Incanthera by subscribing for 363,637 new ordinary Incanthera shares at a price of £5.50 per share.  This investment values Incanthera at a pre-money valuation of approximately £10m and is consistent with the most recent funding round that Incanthera completed in March 2018.  Following this investment, ImmuPharma will have a circa 16% shareholding in Incanthera.

·     ImmuPharma has granted Incanthera a period of exclusivity until 31 December 2018, during which the Company and Incanthera will finalise the terms of a Definitive Licence Agreement for the Nucant technology.  These terms are expected to include, but will not be limited to the following:          

Incanthera will pay a licence payment to ImmuPharma of £1 million, with this payment to be made via the issuance of new ordinary shares in Incanthera.  This payment in shares is separate and will be in addition to the shareholding which Immupharma currently holds as described above;

Incanthera will be responsible for all of the development costs for the Nucant programme; and,

All future commercialisation revenues will be shared equally between the two companies.

Ureka - Divestment process

 

Ureka, ImmuPharma's wholly owned subsidiary, based in Bordeaux, which is carrying out research into treatments for Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) has recently demonstrated success in recognised preclinical studies.

 

Following an extensive review by ImmuPharma's Board of directors, it has been decided that Ureka, whilst having exciting and innovative technologies, is not part of the ongoing strategy of ImmuPharma, which is now fully focused on utilising its resources to develop late stage assets.

 

As such, ImmuPharma, with its advisors, will now commence a process of considering all opportunities to divest Ureka.  The intention is to allow ImmuPharma to divest Ureka, whilst still retaining an interest in any future commercial success.

 

Financial Review

 

ImmuPharma's cash balance at 30 June 2018 was £9.02 million (£2.73 million at 31 December 2017, £3.13 million at 30 June 2017).  Basic and diluted loss per share were 2.94p and 2.94p respectively (30 June 2017: 2.34p and 2.34p).  In line with the Company's current policy, no interim dividend is proposed.

 

Operating loss for the Period was £4.1 million (£3.2 million for the six months ended 30 June 2017).  Research and development expenditure in the Period was £2.5 million (£2.3 million for the six months ended 30 June 2017) reflecting primarily the expenditure related to the LupuzorTM Phase III clinical trial.  Administrative expenses were £1.0 million during the Period (£0.8 million for the six months ended 30 June 2017).  The share based expense was £775k (£131k for the period ended 30 June 2017) which includes a reduction for the National Insurance provision which was nil due to the decrease in share price from 31 December 2017 to 30 June 2018.

 

Given the stage of ImmuPharma's development, the fact that losses have continued to be made is to be expected since there is minimal revenue and business activity is concerned with significant investment in the form of clinical development expenditure, in addition to maintaining the infrastructure of the Company.

 

Current Activities and Outlook

 

The Board has been focused on delivering a business strategy which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, resources and knowhow.  We are excited to be progressing the Managed Access Programme which allows lupus patients early access to LupuzorTM.  In the medium term, we remain focussed on achieving the full regulatory approval of LupuzorTM which we believe has the potential to be a ground breaking drug for lupus patients with blockbuster potential in commercial terms. 

 

Our Nucant programme and Ureka subsidiary have been part of our portfolio for a number of years.  We are equally excited by the potential of both.  We believe the strategy we are pursuing with the collaboration with Incanthera Limited for the Nucant and for divestment of Ureka will create enhance value for shareholders going forward.

 

The Board would like to thank its shareholders, both longstanding and those who participated in the January 2018 fundraising, for their support as well as its staff, corporate and scientific advisers including Simbec-Orion and the CNRS (Centre Nationale de la Recherche Scientifique) for their continued collaboration.

 

Tim McCarthy                                   

Chairman         

 

ImmuPharma PLC

 

CONSOLIDATED INCOME STATEMENT

FOR THE PERIOD ENDED 30 JUNE 2018

 

 

 

 

 

Note

Unaudited

6 months ended

30 June 2018

 

Audited

Year

 ended 31 December

2017

 

Unaudited

6 months ended

30 June 2017

 

 

£

 

£

 

£

Continuing operations

 

 

 

 

 

 

Revenue

1

       73,392

 

150,462

 

86,504

Research and development expenses

 

 (2,455,490)

 

(5,121,388)

 

(2,345,815)

Administrative expenses

 

(992,085)

 

(1,520,356)

 

(796,403)

Share based expense

 

(775,135)

 

(742,752)

 

(131,237)

 

 

 

 

 

 

 

Operating loss

 

(4,149,318)

 

(7,234,034)

 

(3,186,951)

 

 

 

 

 

 

 

Finance costs

 

(29,425)

 

(3,858)

 

(375)

Finance income

 

6,077

 

240,447

 

153,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before taxation

 

(4,172,666)

 

(6,997,445)

 

(3,033,411)

 

 

 

 

 

 

 

Tax

 

110,237

 

774,244

 

(485)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the period

 

(4,062,429)

 

(6,223,201)

 

(3,033,896)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

 

Equity holders of the parent company

 

(4,062,429)

 

(6,223,201)

 

(3,033,896)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per ordinary share

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

2

(2.94)p

 

(4.75)p

 

(2.34)p

 

 

 

 

 

 

 

 

 

 

ImmuPharma PLC

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2018

 

 

 

Unaudited

6 months ended

30 June

 2018

 

Audited

Year

 ended 31 December

2017

 

Unaudited

6 months ended

30 June

 2017

 

£

 

£

 

£

 

 

 

 

 

 

Loss for the financial period

(4,062,429)

 

(6,223,201)

 

(3,033,896)

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income

 

 

 

 

 

Items that may be reclassified subsequently to profit or loss:

 

 

 

 

 

 

Exchange differences on translation of foreign operations


29,459

 


(91,568)

 


(56,133)

 

 

 

 

 

 

 

 

 

 

 

 

Total items that may be reclassified subsequently to profit or loss

29,459

 

(91,568)

 

(56,133)

 

 

 

 

 

 

Other comprehensive loss for the period

 

29,459

 


(91,568)

 


(56,133)

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive loss for the period

(4,032,970)

 

(6,314,769)

 

(3,090,029)

 

 

 

 

 

 

 

 

ImmuPharma PLC

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2018

 

 

Note

Unaudited

30 June

2018

 

Audited

31 December

2017

 

Unaudited

30 June 2017

 

 

 

£

 

£

 

£

 

Non-current assets

 

 

 

 

 

 

 

Intangible assets

 

481,667

 

482,268

 

497,585

 

Property, plant and equipment

 

120,675

 

161,399

 

192,573

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total non-current assets

 

602,342

 

643,667

 

690,158

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Trade and other receivables

 

1,174,720

 

 1,644,128

 

2,439,143

 

Derivative financial asset

 

-

 

-

 

943,861

 

Cash and cash equivalents

 

9,015,630

 

2,729,468

 

3,131,595

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current assets

 

10,190,350

 

4,373,596

 

6,514,599

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Financial liabilities - borrowings

 

138,214

 

142,393

 

119,430

 

Trade and other payables

 

737,035

 

929,569

 

473,867

 

Provisions

 

-

 

57,517

 

33,162

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

875,249

 

1,129,479

 

626,459

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net current assets

 

9,315,101

 

3,244,117

 

5,888,140

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

Financial liabilities - borrowings

 

61,209

 

117,297

 

170,232

 

Provisions

 

-

 

195,989

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net assets

 

9,856,234

 

3,574,498

 

6,480,066

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

Ordinary shares

 

13,946,744

 

13,252,299

 

13,252,298

 

Share premium

 

27,320,143

 

18,728,519

 

18,728,519

 

Merger reserve

 

106,148

 

106,148

 

106,148

 

Other reserves

 

(1,902,921)

 

(2,961,017)

 

(3,316,753)

 

Retained earnings

 

(29,613,880)

 

(25,551,451)

 

(22,362,146)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total equity

 

9,856,234

 

3,574,498

 

6,408,066

 

 

 

 

 

 

 

 

 

 

ImmuPharma PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 30 JUNE 2018

 

 

Share capital

 

Share premium

 

 

Merger

reserve

 

Other reserves -

Acquisition

reserve

 

Other reserves -

Translation

Reserve

 

Other reserves -

Equity shares

to be issued

 

 

 

Retained

Earnings

 

Total

equity

 

 

£

 

£

 

£

 

£

 

£

 

£

 

£

 

£

 

At 1 January 2017

 

12,463,836

 

15,678,054

 

106,148

 

(3,541,203)

 

(1,609.673)

 

1,777,131

 

(19.328.250)

 

5,546,043

 

Loss for the financial period

-

 

-

 

-

 

-

 

-

 

-

 

(3,033,896)

 

(3,033,896)

 

Exchange differences on translation

of foreign operations

-

 

-

 

-

 

-

 

(56,133)

 

-

 

-

 

(56,133)

 

New issue of equity capital

788,462

 

3,311,542

 

-

 

-

 

-

 

-

 

-

 

4,100,004

 

Cost of new issue of equity capital

-

 

(261,077)

 

-

 

-

 

-

 

-

 

-

 

(261,077)

 

Share based payments

-

 

-

 

-

 

-

 

-

 

113,125

 

-

 

113,125

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 30 June 2017

13,252,298

 

18,728,519

 

106,148

 

(3,541,203)

 

(1,665,806)

 

1,890,256

 

(22,362,146)

 

6,408,066

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 1 January 2017

12,463,836

 

15,678,054

 

106,148

 

(3,541,203)

 

(1,609,673)

 

1,777,131

 

(19,328,250)

 

5,546,043

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the financial year

-

 

-

 

-

 

-

 

                   -

 

-

 

(6,223,201)

 

(6,223,201)

 

Exchange differences on translation

of foreign operations

-

 

-

 

-

 

-

 

                         (91,568)

 

-

 

-

 

(91,568)

 

New issue of equity capital

788,463

 

3,311,542

 

-

 

-

 

-

 

-

 

-

 

4,100,005

 

Cost of new issue of equity capital

-

 

(261,077)

 

-

 

-

 

-

 

-

 

-

 

(261,077)

 

Share based payments

-

 

-

 

-

 

-

 

-

 

504,296

 

-

 

504,296

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 31 December 2017 & 1 January 2018

13,252,299

 

18,728,519

 

106,148

 

(3,541,203)

 

(1,701,241)

 

2,281,427

 

(25,551,451)

 

3,574,498

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the financial period

-

 

-

 

-

 

-

 

-

 

-

 

(4,062,429)

 

(4,062,429)

 

Exchange differences on translation

of foreign operations

-

 

-

 

-

 

-

 

29,459

 

-

 

-

 

29,459

 

New issue of equity capital

694,445

 

9,305,555

 

-

 

-

 

-

 

-

 

-

 

10,000,000

 

Cost of new issue of equity capital

-

 

(713,931)

 

-

 

-

 

-

 

-

 

-

 

(713,931)

 

Share based payments

-

 

-

 

-

 

-

 

-

 

1,028,637

 

-

 

1,028,637

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 30 June 2018

13,946,744

 

27,320,143

 

106,148

 

(3,541,203)

 

(1,671,782)

 

3,310,064

 

(29,613,880)

 

9,856,234

 

Attributable to:-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity holders of the parent company

13,946,744

 

27,320,143

 

106,148

 

(3,541,203)

 

(1,671,782)

 

3,310,064

 

(29,613,880)

 

9,856,234

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ImmuPharma PLC

 

CONSOLIDATED STATEMENT OF CASHFLOWS

FOR THE PERIOD ENDED 30 JUNE 2018

 

 

Note

Unaudited

6 months ended

30 June 2018

 

Audited

Year

 ended

31 December

2017

 

Unaudited

6 months ended

30 June

2017

 

 

 

£

 

£

 

£

 

Cash flows from operating activities

 

 

 

 

 

 

 

Cash used in operations

3

(3,150,500)

 

(5,439,079)

 

(3,200,329)

 

Tax

 

213,724

 

1,021,915

 

6,680

 

Interest paid

 

(2,423)

 

(3,858)

 

(375)

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

(2,939,199)

 

 

(4,421,022)

 

(3,194,024)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

(7,946)

 

(25,491)

 

(1,595)

 

Interest received

 

6,077

 

772

 

170

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

(1,869)

 

(24,719)

 

(1,425)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

(Decrease)/increase in bank overdraft

 

             (122)

 

(290)

 

(138)

 

Loan repayments

 

(58,615)

 

(114,386)

 

(80,447)

 

Gross proceeds from issue of new share capital

 

10,000,000

 

4,100,005

 

4,100,004

 

Settlements from sharing agreement                

 

-

 

1,667,380

 

682,360

 

Share capital issue costs

 

(713,931)

 

(261,077)

 

(261,077)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash generated from financing activities

 

9,227,332

 

5,391,632

 

4,440,702

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net  increase in cash and cash equivalents

 

 

6,286,264

 

945,891

 

1,245,253

 

Cash and cash equivalents at start of period

 

2,729,468

 

1,876,718

 

1,876,718

 

 

Effects of exchange rates on cash and

cash equivalents

 

(102)

 

 

(93,141)

 

 

9,624

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

 

9,015,630

 

2,729,468

 

 

3,131,595

 

 

 

 

 

 

 

 

 

                 

 

 

 

ImmuPharma PLC

 

NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE 2018

 

1          ACCOUNTING POLICIES

 

Basis of preparation

 

The interim financial information in this report has been prepared using accounting policies consistent with IFRS as adopted by the European Union. IFRS is subject to amendment and interpretation by the International Accounting Standards Board (IASB) and the IFRS Interpretations Committee and there is an ongoing process of review and endorsement by the European Commission.  The financial information has been prepared on the basis of IFRS to be adopted by the European Union and applicable as at 31 December 2018. The Group has chosen not to adopt IAS 34 "Interim Financial Statements" in preparing the interim financial information.

 

            The accounting policies applied are consistent with those that were applied to the financial statements for the year ending 31 December 2017, with the exception of IFRS 9 "Financial Instruments" and IFRS 15 "Revenue from Contracts with Customers" which are new standards applicable mandatory for the year ended 31 December 2018. These new standards will not have a material impact on the financial statements.

 

             Non-Statutory accounts

 

The financial information set out in this interim report does not constitute the Group's statutory accounts, within the meaning of Section 434 of the Companies Act 2006. The statutory accounts for the year ended 31 December 2017 have been filed with Registrar of Companies. The auditors reported on those accounts; their report was unqualified, did not contain a statement under either Section 498 (2) or Section 498 (3) of the Companies Act 2006 and did not include references to any matters to which the auditor drew attention by way of emphasis.  The financial information for the 6 months ended 30 June 2018 and 30 June 2017 is unaudited.

 

             Copies of this statement will be available on the Company's website - www.immupharma.com.

 

      

 

2              LOSS PER SHARE

               

 

 

Unaudited
6 months ended 30 June 2018

 

Audited

Year ended 31 December

2017

 

Unaudited
6 months ended 30 June 2017

 

£

 

£

 

£

 

 

 

 

 

 

Loss

 

 

 

 

 

Loss for the purposes of basic and diluted loss per share being net loss attributable to equity shareholders

(4,062,429)

 



(6,223,201)

 

(3,033,896)

 

 

 

 

 

 

 

 

 

 

 

 

Number of shares

 

 

 

 

 

Weighted average number of ordinary shares for the purposes of basic loss per share

138,201,316

 

130,902,857

 

129,517,245

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic loss per share

(2.94)p

 

(4.75)p

 

 

 

 

(2.34)p

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted loss per share

(2.94)p

 

(4.75)p

 

(2.34)p

 

 

 

 

 

 

 

 

 

 

 

 

 

There is no difference between basic loss per share and diluted loss per share as the share options and warrants are anti-dilutive.

 

The ImmuPharma group has granted share options in respect of shares to be issued.

 

 

 

3

CASH USED IN OPERATIONS

 

 

 

 

Unaudited

6 months ended

30 June 2018

 

Audited

Year ended 31 December 2017

 

Unaudited

6 months

ended

30 June 2017

 

 

 

 

£

 

£

 

£

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

(4,149,318)

 

(7,234,034)

 

(3,186,951)

 

 

Depreciation & amortisation

81,424

 

138,198

 

61,954

 

 

Share based payments

1,028,637

 

504,296

 

113,125

 

 

Decrease in trade & other receivables

 

358,921

 

643,466

 

34,004

 

 

(Decrease)/increase in trade & other payables

 

(189,656)

 

143,378

 

(322,963)

 

 

(Decrease)/increase in provisions

 

(253,506)

 

238,456

 

18,112

 

 

Gain/(loss) on foreign exchange

 

(27,002)

 

127,161

 

82,390

 

 

 

 

 

 

 

 

 

 

 

 

Cash used in operations

 

 

(3,150,500)

 

 

(5,439,079)

 

 

(3,200,329)

 

 

 

 

 

 

 

 

 

 

                       

 

4

SUBSEQUENT EVENTS

 

 

 

 

On 7 September 2018, ImmuPharma announced that a Heads of Terms agreement was signed with Incanthera Limited.  Under the Heads of Terms agreement, Incanthera Limited will license in and take up the continued clinical development of the Nucant cancer programme as an integral part of its own cancer development portfolio.  As part of the Heads of Terms, ImmuPharma has invested £2 million into Incanthera Limited by subscribing for 363,637 new ordinary Incanthera shares at a price of £5.50 per share.  Following this investment, ImmuPharma will have approximately 16% shareholding in Incanthera Limited.  Under the Heads of Terms, ImmuPharma has granted Incanthera Limited a period of exclusivity until 31 December 2018, during which the two companies will finalise terms of a Definitive License Agreement for the Nucant technology.  These terms are expected to include, but will not be limited to Incanthera Limited paying a license payment to ImmuPharma of £1 million, with this payment being made via the issuance of new ordinary shares in Incanthera Limited.  It is also planned to include confirmation that Incanthera Limited will be responsible for all of the development costs of the Nucant programme and confirmation that all future commercialisation revenues will be shared equally between the two companies.

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IR UVOSRWUAKUAR

ImmuPharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use